IMU Biosciences Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
25
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$53.9M
- Investors
-
12
IMU Biosciences General Information
Description
Operator of an online health diagnostic platform intended to provide medical consultancy and advice to people. The company's platform offers blood test profiles and examines health markers with novel immune mechanisms with precision for diagnosing, monitoring, and treating disease, enabling the healthcare sector to have access to perceptive and cost-effective services to take control of patients' health.
Contact Information
Website
www.imubiosciences.comCorporate Office
- 20 Water Street
- Wood Wharf
- London E14 5GX
- England, United Kingdom
Corporate Office
- 20 Water Street
- Wood Wharf
- London E14 5GX
- England, United Kingdom
IMU Biosciences Timeline
IMU Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 02-Jun-2026 | $53.9M | Completed | Generating Revenue | ||
| 4. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 3. Early Stage VC | 14-Mar-2023 | Completed | Generating Revenue | |||
| 2. Seed Round | 15-May-2019 | $672K | $672K | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
IMU Biosciences Comparisons
Industry
Financing
Details
IMU Biosciences Competitors (4)
One of IMU Biosciences’s 4 competitors is Immunai, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immunai | Venture Capital-Backed | New York, NY | ||||
| Repertoire Immune Medicines | Venture Capital-Backed | Cambridge, MA | ||||
| SomaLogic Operating Company | Formerly PE-Backed | Boulder, CO | ||||
| Adaptive Biotechnologies | Formerly VC-backed | Seattle, WA |
IMU Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
IMU Biosciences Patents
IMU Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026178401-A1 | Methods and systems for prediction of immune checkpoint inhibition therapeutic response and toxicity from an immune signature | Pending | 21-Feb-2025 | ||
| US-20260118362-A1 | Methods and systems for identifying hematopoietic stem cell transplant donors from an immune signature | Pending | 25-Oct-2024 | ||
| WO-2026090549-A1 | Methods and systems for identifying hematopoietic stem cell transplant donors from an immune signature | Pending | 25-Oct-2024 | ||
| AU-2025236321-A1 | Methods and systems for predicting single cell transcriptomic information from flow cytometry data | Pending | 14-Mar-2024 | ||
| US-20250290843-A1 | Methods and systems for predicting single cell transcriptomic information from flow cytometry data | Pending | 14-Mar-2024 | G01N15/1429 |
IMU Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
IMU Biosciences Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| British Business Bank | Lender/Debt Provider | Minority | ||
| IQ Capital Partners | Venture Capital | Minority | ||
| Life Extension Ventures | Venture Capital | Minority | ||
| Meltwind Advisory | Venture Capital | Minority | ||
| Molten Ventures | Venture Capital | Minority |
IMU Biosciences FAQs
-
When was IMU Biosciences founded?
IMU Biosciences was founded in 2019.
-
Where is IMU Biosciences headquartered?
IMU Biosciences is headquartered in London, United Kingdom.
-
What is the size of IMU Biosciences?
IMU Biosciences has 25 total employees.
-
What industry is IMU Biosciences in?
IMU Biosciences’s primary industry is Discovery Tools (Healthcare).
-
Is IMU Biosciences a private or public company?
IMU Biosciences is a Private company.
-
What is IMU Biosciences’s current revenue?
The current revenue for IMU Biosciences is .
-
How much funding has IMU Biosciences raised over time?
IMU Biosciences has raised $54.6M.
-
Who are IMU Biosciences’s investors?
British Business Bank, IQ Capital Partners, Life Extension Ventures, Meltwind Advisory, and Molten Ventures are 5 of 12 investors who have invested in IMU Biosciences.
-
Who are IMU Biosciences’s competitors?
Immunai, Repertoire Immune Medicines, SomaLogic Operating Company, and Adaptive Biotechnologies are competitors of IMU Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
